We demonstrate the ability to interrogate ex vivo response to standard chemotherapy (FOLFOX—combination 5FU, oxaliplatin, and leucovorin) and TGF-βR1 inhibition using pVMTs derived from 4 primary CRC specimens and 2 PDX-derived primary cell lines. This evidence concerns the gene TGFBR1 and colorectal carcinoma.